Flavopiridol in Treating Patients With Recurrent Prostate Cancer

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Alvocidib

Criteria

PATIENT CHARACTERISTICS:

• Performance Status: ECOG 0-2

• Life Expectancy: At least 3 months

• WBC at least 3,000/mm3

• Absolute neutrophil count at least 1,200/mm3

• Platelet count at least 100,000/mm3

• Hemoglobin at least 8 g/dL

• Bilirubin no greater than 1.5 mg/dL

• SGOT no greater than 2.5 times normal

• Creatinine no greater than 1.5 mg/dL

• Prostate-specific antigen at least 10 ng/mL (if bone only disease)

• No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer

• No serious medical illness

• No cord compression symptoms

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy

• No prior suramin therapy

• Prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other concurrent hormonal therapy)

• No prior anti-androgen therapy within 4 weeks of study

• At least 4 weeks since prior radiotherapy

• No prior strontium therapy